Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in neuro-2a neuroblastoma cells

Journal of Neuroscience Research

Volumn 85, Issue 9, 2007, Pages 2017-2025

  Deguil, Julie ^a   Jailloux, David ^a   Page, Guylène ^a   Fauconneau, Bernard ^a,b   Houeto, Jean Luc ^a,b   Philippe, Michel ^c   Muller, Jean Marc ^c   Pain, Stéphanie ^a,b,d  

^a Pôle de Biologie Santé   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UFR SFA   (France)

^d Research Group on Brain Aging   (France)

Author keywords

MPP+, translational control; Neuroblastoma cells; Neuroprotection; PACAP; VIP

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE R; S6 KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 2ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SUBSTANTIA NIGRA;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; FLUORESCENT DYES; INDOLES; MICE; MPTP POISONING; NEUROBLASTOMA; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; SIGNAL TRANSDUCTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34447337779     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21318     Document Type: Article

References (58)

1. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y. 1997. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12:25-31.
2. Arimura A, Somogyvari-Vigh A, Weill C, Fiore RC, Tatsuno I, Bay V, Brenneman DE. 1994. PACAP functions as a neurotrophic factor. Ann NY Acad Sci 739:228-243.
3. Arimura A. 1998. Perspectives on pituitary adenylate cyclase-activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous system. Jpn J Physiol 48:301-331.
4. Bando Y, Onuki R, Katayama T, Manabe T, Kudo T, Taira K, Tohyama M. 2005. Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease. Neurochem Int 46:11-18.
5. Barbeau A. 1968. Dopamine and dopamine metabolites in Parkinson's disease -a review. Proc Aust Assoc Neurol 5:95-100.
6. Brenneman DE, Neale EA, Foster GA, d'Autremont SW, Westbrook GL. 1987. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J Cell Biol 104:1603-1610.
7. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. 1988. Neuronal cell kitting by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335:639-642.
8. Chang RCC, Suen KC, Ma CH, Elyaman W, Ng H, Hugon J. 2002a. Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2-alpha in neuronal degeneration. J Neurochem 83:1215-1225.
9. Chang RC, Wong AK, Ng HK, Hugon J. 2002b. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport 13:2429-2432.
10. Chiba K, Trevor A, Catagnoli N Jr. 1985. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128:1228-1232.
11. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. 2005. Cell type specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709-1725.
12. Clemens MJ. 1994. Regulation of eukaryotic protein synthesis by protein kinases that phosphorylate initiation factor eIF-2. Mol Biol Rep 19:201-210.
13. Clemens MJ. 2001. Translational regulation in cell stress and apoptosis. Role of the eIF4E binding proteins. J Cell Mol Med 5:221-239.
14. Dejda A, Sokolowska P, Nowak JZ. 2005. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 57:307-320.
15. Delgado M, Jonakait GM, Ganea D. 2002. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39:148-161.
16. Delgado M, Ganea D. 2003. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17:944-946.
17. Deutsch PJ, Sun Y. 1992. The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. J Biol Chem 267:5108-5113.
18. Dever TE. 2002. Gene-specific regulation by general translation factors. Cell 108:545-556.
19. Dufner A, Thomas G. 1999 Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253:100-109.
20. Duncan RF, Hershey JW. 1989. Protein synthesis and protein phosphorylation during heat stress, recovery, and adaptation. J Cell Biol 109:1467-1481.
21. Dux E, Oschlies U, Wiessner C, Hossmann KA. 1992. Glutamate-induced ribosomal disaggregation abd ultrastructural changes in rat cortical neuronal culture: protective effect of horse serum. Neurosci Lett 141:173-176.
22. Fall CP, Bennett JP Jr. 1999. Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 55:620-628.
23. Gingras AC, Raught B., Sonenberg N. 1999. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913-963.
24. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. 2001a. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15:2852-2864.
25. Gingras AC, Raught B, Sonenberg N. 2001b. Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol 27:143-174.
26. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Varela N, Delgado M. 2005. Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 9:923-929.
27. Granville DJ, Gottlieb RA. 2002. Mitochondria: regulators of cell death and survival. Scientific World Journal 2:1569-1578.
28. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
29. Holtz WA, O'Malley KL. 2003. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367-19377.
30. Kiessling M, Xie Y, Kleihues P. 1984. Regional impairment of protein synthesis in the rat brain during bicuculline-induced seizures. Brain Res 296:1-13.
31. Laburthe M, Couvineau A, Marie JC. 2002. VPAC receptors for VIP and PACAP. Recept Channels 8:137-153.
32. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J. 2005. mTOR/p70S6K signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 94:215-225.
33. Onoue S, Endo K, Yajima T, Kashimoto K. 2002a. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and cytotoxicity. Regul Pept 107:43-47.
34. Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. 2002b. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 23:1471-1478.
35. Paccalin M, Pain Barc S, Pluchon C, Paul C, Bazin H, Gil R, Hugon J. 2005. The relation between p70S6k expression in lymphocytes and the decline of cognitive test scores in patients with Alzheimer disease. Arch Int Med 165:2428-2429.
36. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R, Hugon J. 2006. mTOR and PKR Levels in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement Ger Cog Dis 22:320-326.
37. Patel J, McLeod LE, Vries RG, Flynn A, Wang X, Proud CG. 2002. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur J Biochem 269:3076-3085.
38. Proud CG. 1992. Protein phosphorylation in translational control [review]. Curr Top Cell Regul 32:243-369.
39. Rattan SI. 1996. Synthesis, modifications, and turnover of proteins during aging. Exp Gerontol 31:33-47.
40. Raught B, Gingras AC, Sonenberg N. 2001. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 98:7037-7044.
41. Reglodi D, Lubics A, Tamas A, Szalontay L, Lengvari I. 2004a. Pituitary adenylate cyclase-activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav Brain Res 151:303-312.
42. Reglodi D, Tamas A, Lubics A, Szalontay L, Lengvari I. 2004b. Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra. Regul Pept 123:85-94.
43. Reichmann H, Janetzky B. 2000. Mitochondrial dysfunction: a pathogenetic factor in Parkinson's disease. J Neurol 247:63-68.
44. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. 2002. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 22:10690-10698.
45. Saelens X, Kalai M, Vandenabeele P. 2001. Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 276:41620-41628.
46. Said SI, Mutt V. 1970. Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217-1218.
47. Shoge K, Mishima HK, Saitoh T, Ishihara K, Tamura Y, Shiomi H, Sasa M. 1998. Protective effects of vasoactive intestinal peptide against delayed glutamate neurotoxicity in cultured retina. Brain Res 809:127-136.
48. Schmelzle T, Hall MN. 2000. TOR, a central controller of cell growth [review]. Cell 103:253-262.
49. Schultz W. 1984. Recent physiological and pathophysiological aspects of Parkinsonian movement disorders. Life Sci 34:2213-2223.
50. Somogyvari-Vigh A, Reglodi D. 2004. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Rev Curr Pharm Des 10:2861-2889.
51. Suen KC, Yu M, So KF, Chang RC, Hugon J. 2003. Upstream signaling pathways leading to the activation of double-stranded RNA-dependent serine/threonine protein kinase in beta-amyloid peptide neurotoxicity. J Biol Chem 278:49819-49827.
52. Takei N, Skoglosa Y, Lindholm D. 1998. Neurotrophic and neuroprotective effects of Pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. J Neurosci Res 54:698-706.
53. Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H. 1998. Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84:801-812.
54. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. 2000a. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.
55. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H. 2000b. The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci U S A 97:13390-13395.
56. Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H, Gonzalez BJ. 2003. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72:303-316.
57. Waschek JA. 2002. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 24:14-23.
58. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ. 1999. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423-1429.